R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma

  • Thierry Lamy
    Hematology Department, Rennes University Hospital, INSERM Research Unit 1236, Rennes, France;
  • Gandhi Damaj
    Hematology Department, Centre Hospitalier Universitaire (CHU) d’Amiens, INSERM U1245, Amiens, France;
  • Pierre Soubeyran
    Bergonié Bordeaux Institute and Bordeaux University, Bordeaux, France;
  • Emmanuel Gyan
    Hematology and Cell Therapy Department, Clinical Investigation Center (CIC) INSERM U1415, CHU de Tours, Université François Rabelais, Tours, France;
  • Guillaume Cartron
    Hematology Department, CHU Montpellier, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 5235, Montpellier, France;
  • Krimo Bouabdallah
    Hematology and Cell Therapy Department, University Hospital of Bordeaux, Bordeaux, France;
  • Rémy Gressin
    Onco Hematology Department, Hospital University Grenoble, INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes, Site Santé, La Tronche, Grenoble, France;
  • Jérôme Cornillon
    Hematology Department, Cancer Institute Lucien Neuwirth, Saint-Priest-en-Jarez, France;
  • Anne Banos
    Hematology Department, Centre Hospitalier de la Côte Basque, Bayonne, France;
  • Katell Le Du
    Hematology Department, Clinique Victor Hugo, Le Mans, France;
  • Mohamed Benchalal
    Radiotherapy Department, Centre Eugène Marquis, Rennes, France;
  • Marie-Pierre Moles
    Hematology Department, CHU d’Angers, Angers, France;
  • Steven Le Gouill
    Hematology Department, CHU de Nantes, University of Nantes, INSERM team 10 UMR 892, Institut de Recherche en Santé de l’Université de Nantes, CIC Hospital Hôtel Dieu, Nantes, France;
  • Joel Fleury
    Oncology Department, Médicale-Pôle Santé République, Clermont-Ferrand, France;
  • Pascal Godmer
    Hematology Department, Centre Hospitalier de Vannes, Vannes, France;
  • Hervé Maisonneuve
    Hematology Department, Centre Hospitalier Départemental de Vendée, La Roche-Sur-Yon, France;
  • Eric Deconinck
    Hematology Department, Centre Hospitalier Regional Universitaire Besançon, INSERM UMR 1098, Université de Franche-Comté, Besançon, France;
  • Roch Houot
    Hematology Department, Rennes University Hospital, INSERM UMR 1236, Rennes, France;
  • Kamel Laribi
    Hematology Department, Centre Hospitalier du Mans, Le Mans, France;
  • Jean Pierre Marolleau
    Hematology and Cell Therapy Department, CIC U1415, Department EA4666, CHU Amiens, Amiens, France;
  • Olivier Tournilhac
    Hematology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France;
  • Bernard Branger
    Health Network of Pays de Loire, Nantes, France;
  • Anne Devillers
    Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France;
  • Jean Philippe Vuillez
    Imaging Nuclear Medicine Department and Radiopharmaceutical and Bioclinical Department, CHU de Grenoble, INSERM U1039, Grenoble University, Grenoble, France;
  • Thierry Fest
    INSERM UMR 1236, Rennes University, Etablissement Français du Sang and Laboratoire d’Hématologie, CHU de Rennes, Rennes, France;
  • Philippe Colombat
    Hematology and Cell Therapy Department, CIC INSERM U1415, CHU de Tours, Université François Rabelais, Tours, France;
  • Valérie Costes
    Pathology Department, CHU Montpellier, Montpellier, France;
  • Vanessa Szablewski
    Pathology Department, CHU Montpellier, Montpellier, France;
  • Marie C. Béné
    Hematology Biology, Nantes University Hospital, Nantes, France; and
  • Vincent Delwail
    Hematology and Cell Therapy Department, CIC INSERM U1415, CHU de Poitiers, and CIC INSERM 1402, Université de Poitiers, Poitiers, France

書誌事項

公開日
2018-01-11
DOI
  • 10.1182/blood-2017-07-793984
公開者
American Society of Hematology

この論文をさがす

説明

<jats:title>Key Points</jats:title> <jats:p>For early-stage DLBCL, R-CHOP alone is not inferior to R-CHOP followed by RT.</jats:p>

収録刊行物

  • Blood

    Blood 131 (2), 174-181, 2018-01-11

    American Society of Hematology

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ